Real-world data from 24 UK centres for the use of nintedanib for progressive fibrosing interstitial lung disease

被引：0

作者：

Dixon, Giles ^{[1
]}

Hague, Samuel ^{[2
]}

Mulholland, Sarah ^{[2
]}

Khin, Aye Myat Noe ^{[3
]}

Thould, Hannah ^{[3
]}

Connon, Roisin ^{[4
]}

Minnis, Paul ^{[4
]}

Murtagh, Eoin ^{[4
]}

Khan, Fasihul ^{[5
]}

Toor, Sameen ^{[5
]}

Lawrence, Alexandra ^{[6
]}

Naqvi, Marium ^{[6
]}

West, Alex ^{[6
]}

Coker, Robina ^{[7
]}

Ward, Katie ^{[7
]}

Yazbeck, Leda ^{[7
]}

Hart, Simon ^{[8
]}

Garfoot, Theresa ^{[9
]}

Newman, Kate ^{[9
]}

Rivera-Ortega, Pilar ^{[9
]}

Stranks, Lachlan ^{[9
]}

Beirne, Paul ^{[10
]}

Bradley, Jessica ^{[10
]}

Rowan, Catherine ^{[10
]}

Agnew, Sarah ^{[11
]}

Ahmad, Mahin ^{[11
]}

Spencer, Lisa G. ^{[11
]}

Aigbirior, Joshua ^{[12
]}

Fahim, Ahmed ^{[12
]}

Wilson, Andrew M. ^{[13
]}

Butcher, Elizabeth ^{[14
]}

Chong, Sy Giin ^{[14
]}

Saini, Gauri

Zulfikar, Sabrina ^{[15
]}

Chua, Felix ^{[16
]}

George, Peter M. ^{[16
]}

Kokosi, Maria ^{[16
]}

Kouranos, Vasileios ^{[16
]}

Molyneaux, Philip ^{[16
]}

Renzoni, Elisabetta ^{[16
]}

Vitri, Benedetta ^{[16
]}

Wells, Athol U. ^{[16
]}

Nicol, Lisa M. ^{[17
]}

Bianchi, Stephen ^{[18
]}

Kular, Raman ^{[18
]}

Liu, Huajian ^{[19
]}

John, Alexander ^{[19
]}

Barth, Sarah ^{[20
]}

Wickremasinghe, Melissa ^{[20
]}

Forrest, Ian A. ^{[21
]}

机构：

[1] Univ Exeter, Exeter, Devon, England

[2] North Bristol NHS Trust, Bristol, Avon, England

[3] Royal Devon Univ Healthcare NHS Fdn Trust, South West Peninsula ILD Network, Exeter, Devon, England

[4] Northern Hlth & Social Care Trust, Antrim Area Hosp, Antrim, North Ireland

[5] Univ Hosp Leicester NHS Trust, Glenfield Hosp, Leicester, Leics, England

[6] Guys & St Thomas Hosp NHS Fdn Trust, London, England

[7] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, London, England

[8] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England

[9] Manchester Univ NHS Fdn Trust, Wythenshawe Hosp, Interstitial Lung Dis Unit, Manchester, Lancs, England

[10] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England

[11] Liverpool Univ Hosp NHS Fdn Trust, Aintree Hosp, Liverpool Interstitial Lung Dis Serv, Liverpool, Merseyside, England

[12] Royal Wolverhampton NHS Trust, New Cross Hosp, Wolverhampton, England

[13] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Norwich, Norfolk, England

[14] Nottingham Univ Hosp NHS Trust, Nottingham, England

[15] Oxford Univ Hosp NHS Fdn Trust, Oxford, England

[16] Royal Brompton & Harefield Hosp, London, England

[17] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland

[18] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England

[19] Southern Hlth & Social Care Trust, Portadown, North Ireland

[20] Imperial Coll Healthcare NHS Trust, St Marys Hosp, London, England

[21] Newcastle Tyne Hosp NHS Fdn Trust, Newcastle, England

[22] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England

[23] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[24] Univ Hosp Morecambe Bay NHS Fdn Trust, Lancashire & South Cumbria ILD Serv, Lancaster, England

[25] Univ Hosp North Midlands NHS Trust, Stoke On Trent, Staffs, England

[26] Royal United Hosp Bath NHS Fdn Trust, Bath, Avon, England

[27] Univ Exeter, Dept Math & Stat, Fac Environm Sci & Econ, Exeter, Devon, England

[28] Univ Exeter Exeter, Dept Clin & Biomed Sci, Exeter, Devon, England

[29] Royal Devon Univ Healthcare NHS Fdn Trust, Exeter, Devon, England

来源：

EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷

关键词：

D O I：

10.1183/13993003.congress-2023.PA404

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：4

共 50 条

[21] Real-world use of Exposure Screening Questionnaires in Occupational & Interstitial Lung Disease clinics in Birmingham, UK
Nettleton, Kimberley
Huntley, Christopher C.
Walters, Gareth I.
Burge, P. Sherwood
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[22] Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort?
Ho, Gen Nen
Douglas, Karen May Jane
RHEUMATOLOGY ADVANCES IN PRACTICE, 2023, 7 (02)
[23] Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
Vincent Cottin
Fernando J. Martinez
R. Gisli Jenkins
John A. Belperio
Hideya Kitamura
Maria Molina-Molina
Inga Tschoepe
Carl Coeck
Dirk Lievens
Ulrich Costabel
Respiratory Research, 23
[24] Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
Inoue, Yoshikazu
Wells, Athol U.
Song, Jin Woo
Xu, Zuojun
Kitamura, Hideya
Suda, Takafumi
Okamoto, Masaki
Mueller, Heiko
Coeck, Carl
Rohr, Klaus B.
Kolb, Martin
Brown, Kevin K.
RESPIROLOGY, 2023, 28 (05) : 465 - 474
[25] Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
Cottin, Vincent
Martinez, Fernando J.
Jenkins, R. Gisli
Belperio, John A.
Kitamura, Hideya
Molina-Molina, Maria
Tschoepe, Inga
Coeck, Carl
Lievens, Dirk
Costabel, Ulrich
RESPIRATORY RESEARCH, 2022, 23 (01)
[26] Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Lotte Westerink
Jelmer Lennart Jens Nicolai
Maarten Jacobus Postma
Job Frank Martien van Boven
Cornelis Boersma
PharmacoEconomics - Open, 2022, 6 : 647 - 656
[27] Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Westerink, Lotte
Nicolai, Jelmer Lennart Jens
Postma, Maarten Jacobus
van Boven, Job Frank Martien
Boersma, Cornelis
PHARMACOECONOMICS-OPEN, 2022, 6 (05) : 647 - 656
[28] Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
Matteson, Eric
Antin-Ozerkis, Danielle
Bonella, Francesco
Chaudhuri, Nazia
Cottin, Vincent
Mueller, Heiko
Coeck, Carl
Rohr, Klaus
Wuyts, Wim
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 260 - 262
[29] DELIVERY OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROTIC INTERSTITIAL LUNG DISEASE: EXPERIENCE FROM A UK TERTIARY CENTRE
Martinovic, J. L.
Nagvi, M.
West, A.
THORAX, 2022, 77 : A95 - A96
[30] Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analyses from the INBUILD Trial
Kolb, M. R.
Flaherty, K. R.
Silva, R. S.
Prasse, A.
Patel, N. M.
Vancheri, C.
Quaresma, M.
Goeldner, R.
Stowasser, S.
Schlenker-Herceg, R.
Wells, A. U.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201

← 1 2 3 4 5 →